Starling Oncology, Inc. (STLN): who owns it and who trades it
As of Nov 16, 2026, STLN insiders reported 12 open-market sales worth $14.2M and 17 purchases worth $2.9M in the last 12 months, with 18% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jorey Chernett (10% owner), with $11.4M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Starling Oncology
From the latest filingsOverall: about as much buying as selling. Congress mostly sold. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, STLN insiders reported $2.9M of open-market purchases and $14.2M of sales. 18% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Jorey Chernett | 10% owner | Purchase | 48,294 | $3.65 | $176K | Form 4 |
| Nov 6, 2026 | Jorey Chernett | 10% owner | Sale | 2.85M | $3.99 | $11.4M | Form 4 |
| Aug 21, 2026 | Brad Hively | Director | Sale plan | 298,853 | $6.51 | $1.9M | Form 4 |
| Aug 14, 2026 | Jorey Chernett | 10% owner | Purchase | 12,000 | $6.54 | $78.5K | Form 4 |
| Jul 21, 2026 | Jorey Chernett | 10% owner | Purchase | 18,000 | $5.27 | $94.9K | Form 4 |
| Jul 14, 2026 | Yale Podnos | Chief Medical Officer | Sale plan | 5,478 | $6.35 | $34.8K | Form 4 |
| Jul 14, 2026 | Yale Podnos | Chief Medical Officer | Sale plan | 17,974 | $6.43 | $116K | Form 4 |
| Jul 10, 2026 | Jorey Chernett | 10% owner | Purchase | 15,000 | $5.85 | $87.8K | Form 4 |
| Jun 23, 2026 | Jorey Chernett | 10% owner | Purchase | 18,000 | $5.02 | $90.4K | Form 4 |
| Jun 8, 2026 | Yale Podnos | Chief Medical Officer | Sale plan | 23,451 | $5.38 | $126K | Form 4 |
| Jun 4, 2026 | Jorey Chernett | 10% owner | Purchase | 12,000 | $4.75 | $57K | Form 4 |
| May 20, 2026 | Jorey Chernett | 10% owner | Purchase | 33,500 | $4.07 | $136K | Form 4 |
| May 19, 2026 | Jorey Chernett | 10% owner | Purchase | 5,000 | $4.05 | $20.2K | Form 4 |
| May 19, 2026 | Jorey Chernett | 10% owner | Purchase | 30,000 | $4.09 | $123K | Form 4 |
| Apr 16, 2026 | Mohit Kaushal | Director | Sale plan | 38,433 | $3.50 | $135K | Form 4 |
| Apr 14, 2026 | Mohit Kaushal | Director | Sale plan | 57,286 | $3.50 | $201K | Form 4 |
| Apr 9, 2026 | Jorey Chernett | 10% owner | Purchase | 20,000 | $3.10 | $62K | Form 4 |
| Mar 27, 2026 | Jorey Chernett | 10% owner | Purchase | 27,429 | $2.96 | $81.2K | Form 4 |
| Mar 26, 2026 | Jorey Chernett | 10% owner | Purchase | 50,000 | $3.15 | $158K | Form 4 |
| Mar 24, 2026 | Jorey Chernett | 10% owner | Purchase | 125,000 | $3.11 | $389K | Form 4 |
| Mar 20, 2026 | Jorey Chernett | 10% owner | Purchase | 25,000 | $3.35 | $83.8K | Form 4 |
| Mar 17, 2026 | Jorey Chernett | 10% owner | Purchase | 75,000 | $3.42 | $256K | Form 4 |
| Mar 16, 2026 | Jorey Chernett | 10% owner | Purchase | 60,985 | $3.29 | $201K | Form 4 |
| Mar 13, 2026 | Jorey Chernett | 10% owner | Purchase | 263,000 | $2.92 | $768K | Form 4 |
| Jan 2, 2026 | Robert Ross Carter | CFO | Sale | 247 | $3.56 | $879 | Form 4 |
| Dec 15, 2025 | Brad Hively | Director | Sale | 13,333 | $3.77 | $50.3K | Form 4 |
| Nov 18, 2025 | Mark L Pacala | Director | Sale | 46,630 | $4.00 | $187K | Form 4 |
| Nov 18, 2025 | Mark L Pacala | Director | Sale | 2,160 | $4.00 | $8.6K | Form 4 |
| Nov 18, 2025 | Mark L Pacala | Director | Sale | 1,210 | $4.00 | $4.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jorey Chernett | 10% owner | $2.9M | $11.4M | Nov 9, 2026 |
| Brad Hively | Director | – | $2M | Aug 21, 2026 |
| Mohit Kaushal | Director | – | $335K | Apr 16, 2026 |
| Yale Podnos | Chief Medical Officer | – | $277K | Jul 14, 2026 |
| Mark L Pacala | Director | – | $200K | Nov 18, 2025 |
| Robert Ross Carter | Chief Financial Officer | – | $879 | Jan 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
STLN short interest
Moderate short interest. 6.7% of STLN shares are sold short: about 1 share in 15. Over the last 6 reports the number of shares short went down 1%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.84M STLN shares were sold short, 6.7% of the shares outstanding, up 4.7% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 5.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.84M | 6.71% | +5% | 1.26M | 5.4 |
| Oct 15, 2026 | 6.54M | 6.41% | -4% | 1.16M | 5.6 |
| Sep 30, 2026 | 6.79M | 6.67% | -4% | 1.58M | 4.3 |
| Sep 15, 2026 | 7.05M | 6.92% | +3% | 959,365 | 7.3 |
| Aug 31, 2026 | 6.82M | 6.69% | -1% | 1.22M | 5.6 |
| Aug 14, 2026 | 6.88M | 6.75% | -4% | 1.96M | 3.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded STLN
Since Nov 17, 2024, 1 member of Congress reported 0 purchases and 5 sales of STLN. The latest was a sale by Richard Blumenthal on Sep 23, 2026, reported Oct 26, 2026.
Purchases 0Sales 5
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Richard Blumenthal (D-CT) | Partial sale | $1K–$15K | Spouse | Oct 26, 2026 | Report |
| Sep 22, 2026 | Richard Blumenthal (D-CT) | Partial sale | $1K–$15K | Spouse | Oct 26, 2026 | Report |
| Sep 22, 2026 | Richard Blumenthal (D-CT) | Partial sale | $15K–$50K | Spouse | Oct 26, 2026 | Report |
| Sep 18, 2026 | Richard Blumenthal (D-CT) | Partial sale | $1K–$15K | Spouse | Oct 26, 2026 | Report |
| Sep 18, 2026 | Richard Blumenthal (D-CT) | Partial sale | $15K–$50K | Spouse | Oct 26, 2026 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Starling Oncology company events
Starling Oncology filed 15 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, cyberattack). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 2, 2026LeadershipBrad Hively notified Starling Oncology, Inc. of his decision to not stand for re-election to the Board of the Directors of the Company at its 2027 annual meeting of stockholders. Filing
- Aug 21, 2026AgreementStarling Oncology Management, Limited Liability Company, a wholly owned subsidiary of Starling Oncology, Inc., entered into a Credit Agreement among SOM, LLC, such other persons joined thereto as a borrower from time to time, and Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL, as lender. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Aug 3, 2026RulesChanged its bylaws or articles. Filing
- Jul 7, 2026AgreementThe Oncology Institute, Inc. entered into a Credit Agreement, by and among the Company, the lenders from time to time party thereto, and Orbimed Opportunities (CA) V LLC, as the initial lender and administrative agent. Filing
- Jun 18, 2026VoteReported shareholder vote results. Filing
- May 22, 2026CyberattackThe Oncology Institute, Inc. is providing this disclosure, as a follow-up to its voluntary disclosure in Item 7.01 of a Current Report on Form 8-K filed on November 6, 2025, regarding a cybersecurity incident affecting a software service provider utilized by the Company. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 13, 2026AnnouncementShared information with investors. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Feb 23, 2026LeadershipAppointment of New Director Through action taken by Unanimous Written Consent, effective February 23, 2026, the Board of Directors of The Oncology Institute, Inc. filled a vacancy on the Board by appointing Kimberly Tzoumakas to the Board. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Jan 7, 2026LeadershipAppointment of New Director Through action taken by Unanimous Written Consent, effective January 2, 2026, the Board of Directors of The Oncology Institute, Inc. filled a vacancy on the Board by appointing Mark D. Stolper to the Board. Filing
- Dec 1, 2025LeadershipGabriel Ling resigned from the Board of Directors of The Oncology Institute, Inc., effective on December 1, 2025. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Starling Oncology financials
Famous investors that hold STLN
5 of the 50 well-known investors we track reported holding STLN in their latest 13F filing. The largest position is Jim Simons's, worth $7.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.18M | $7.4M | 0.0% | -14% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 992,853 | $6.3M | 0.0% | +11% |
| Israel Englander · Millennium Management | Q3 2026 | 625,522 | $4M | 0.0% | +546% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 411,629 | $2.6M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 111,271 | $703K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named STLN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | Chernett Jorey | 13G/A | 5.6% |
| Nov 13, 2026 | Chernett Jorey | 13G/A | 5.6% |
Questions about Starling Oncology, Inc. (STLN) stock
Are STLN insiders buying or selling?
In the last 12 months, STLN insiders reported 17 open-market purchases worth $2.9M and 12 sales worth $14.2M. The latest trade was on Nov 9, 2026. See every trade.
What is the short interest in STLN?
As of Oct 30, 2026, 6.84M STLN shares were sold short, 6.7% of the shares outstanding, up 4.7% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 5.4 trading days (days to cover). See the history.
Have members of Congress traded STLN?
Yes. 1 member of Congress reported 0 purchases and 5 sales of STLN since Nov 17, 2024. The latest was reported on Oct 26, 2026. See the trades.
Which famous investors hold STLN?
5 of the 50 well-known investors we track reported STLN in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $7.4M. See all holders.
Executive pay
Starling Oncology's chief executive was paid a total of $1.9M for the year ended Dec 31, 2025, up 73% from $1.1M the year before. In the last 12 months, Starling Oncology's executives and directors bought no stock on the open market and sold $2.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.